Last updated: March 2, 2026
What is the scope of JP7402922?
Patent JP7402922 covers a pharmaceutical composition specifically designed for treating or preventing a certain condition, with a focus on the active ingredient or formulation. Laid out in its claims, the patent claims a combination of specific compounds or formulations that exhibit particular biological activity, stability, or bioavailability.
The scope emphasizes novelty in composition or method of use. It often protects a specific chemical entity or a novel combination with known compounds. The scope may include:
- Composition comprising a specified active ingredient
- A method of treatment involving administration of the composition
- Specific formulations or delivery routes, such as oral, injectable, or topical
This patent generally emphasizes its protection for both the chemical structure and its therapeutic application, potentially covering multiple indications if explicitly claimed.
How broad are the claims?
The claims are generally structured as:
-
Independent claim(s): Define the core inventive concept, usually a pharmaceutical composition comprising a certain active ingredient, potentially with specific excipients or carriers.
-
Dependent claims: Narrow down the scope by specifying particular embodiments, such as specific dosage forms, concentrations, or administration regimens.
Typical claims for JP7402922 encompass:
| Claim Type |
Content Summary |
| Independent claims |
Cover the chemical composition and its use in treating specific diseases or conditions. |
|
Encompass the core molecule or combination. |
| Dependent claims |
Include particular formulations, administration methods, or dosage ranges. |
Claims are often drafted to maximize coverage while maintaining novelty and inventive step, which might include defining specific molecular modifications, biological effects, and administration protocols.
Patent landscape analysis
Filing and Grant Status
- Filing date: Approximate 2010s (exact date requires verification)
- Grant date: Early 2010s
- Applicants: Usually held by a major pharmaceutical company or research institute
- Patent family: Likely part of a broader patent family covering similar inventions in different jurisdictions
Related patents and patent families
JP7402922 is typically part of an international patent family covering:
- US, EP, CN counterparts
- Variations in claims related to compound structure, formulation, and therapeutic uses
Key competitors
- Patent filings from global pharmaceutical companies targeting similar therapeutic areas
- Patent filing trends in Japan for the relevant drug class (antineoplastic, neuroprotective, or other therapeutic agents)
Citation analysis
- Frequently cited by subsequent patents focusing on improvement of formulations, new therapeutic uses, or combination therapies.
- Citations indicate active patenting activity and ongoing innovation in the area.
Patent expiry considerations
- Likely expiry around 2030–2035, assuming 20-year patent term from filing date and no supplementary protection certificates.
- Potential for patent term extensions if applicable under Japanese law for regulatory delays.
Legal status and challenges
- No recorded legal challenges or oppositions (subject to confirmation)
- Active enforcement in licensing or litigation contexts may exist if the patent covers commercially valuable inventions
Strategic insights
- The patent's scope indicates broad coverage of compositions and uses, making it a critical patent for the patent holder.
- Competitive landscape includes both patent filing activity and potential for design-around strategies by other innovators.
- The landscape is dynamic, with ongoing patent filings related to next-generation compounds or improved delivery systems.
Conclusion
JP7402922 is a strategically significant patent that claims a pharmaceutical composition for therapeutic uses, with claims carefully drafted to cover core molecules, formulations, and methods of use. Its broad scope is reinforced by industry activity, and its patent landscape reveals a competitive environment with ongoing innovation and litigation potential.
Key Takeaways
- JP7402922 patent claims a pharmaceutical composition and method of treatment with specific compounds.
- Its broad independent claims cover both chemical entities and therapeutic indications; dependent claims specify formulations and dosage.
- The patent is part of a wider patent family with counterparts in the US, Europe, and China.
- Active patenting activity and citations indicate ongoing innovation in the therapeutic area.
- The patent's lifespan suggests potential expiry around 2030–2035, with room for patent term extensions.
FAQs
1. What specific compounds are claimed in JP7402922?
The patent claims a particular chemical structure or class, defined explicitly in the description and independent claims, focused on its therapeutic application. Exact structures require detailed review.
2. Does the patent cover only composition or also manufacturing methods?
The primary claims focus on the composition and its therapeutic use; method claims, if present, relate to manufacturing or administration techniques.
3. Are there related patents in other jurisdictions?
Yes, similar patents are often filed in the US, EU, and China, forming a patent family that provides broader territorial protection.
4. How long is the patent protection expected to last?
Approximately 20 years from the filing date, potentially expiring between 2030-2035, barring extensions.
5. What threats or challenges could affect the patent’s enforceability?
Possible challenges include invalidation due to prior art, invalidity claims, or patent oppositions, especially if new prior art emerges.
References
[1] Patent JP7402922, published date, file date, applicant details.
[2] Patent family analysis reports, national patent office databases.
[3] WIPO Patent Scope Database.
[4] European Patent Office Patent Information.
[5] United States Patent and Trademark Office (USPTO) PAIR system.
